Log in to search using one of your social media accounts:

 

Why Do Physicians Overtreat Elderly Breast Cancer Patients?
Drs Kathy Miller and Reshma Jagsi on the reasons behind practitioners'reluctance to omit radiation therapy in older patients. (Source: Medscape Oncology)
Source: Medscape Oncology - February 1, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Late Recurrence in ER- Positive Breast Cancer: Banking on Biomarkers
Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy. (Source: Medscape Oncology)
Source: Medscape Oncology - January 17, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Neoadjuvent treatment for breast cancer - not living up to the promise
Neoadjuvant chemotherapy for breast cancer is a new strategy that was introduced towards the end of the 20th century with the aim of reducing tumour size - rendering an otherwise inoperable tumour operable, allowing more conservative surgery, and hopefully improving overall survival. Although data indicate that the first rationale remains valid,... (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 11, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

neoadjuvant treatment for breast cancer - not living up to the promise
Neoadjuvant chemotherapy for breast cancer is a new strategy that was introduced towards the end of the 20th century with the aim of reducing tumour size - rendering an otherwise inoperable tumour operable, allowing more conservative surgery, and hopefully improving overall survival. Although data indicate that the first rationale remains valid,... (Source: The BMJ Podcast)
Source: The BMJ Podcast - January 11, 2018 Category: General Medicine Authors: BMJ talk medicine Source Type: podcasts

Will Immunotherapy Be a PANACEA for Breast Cancer?
Drs Kathy Miller and Sherene Loi discuss advances in immunotherapy for breast cancer, particularly in HER2-positive disease and TNBC. (Source: Medscape Oncology)
Source: Medscape Oncology - January 2, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Takeaways From Dr. Kaklamani From SABCS 2017
What are the highlights from the 2017 San Antonio Breast Cancer Symposium (SABCS). Dr. Virginia Kaklamani, Professor Medicine at UT Health Science Center San Antonio and Leader of the Breast Cancer Pr... Author: patientpower Added: 12/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - December 30, 2017 Category: Cancer & Oncology Source Type: podcasts

For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go
Although the study didn't turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab. (Source: Medscape Oncology)
Source: Medscape Oncology - December 29, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Does Breast Cancer Risk REACT to Celecoxib?
Does this COX-2 inhibitor alter breast cancer risk? Dr Kathy Miller discusses the results of the REACT trial with its primary investigator, Dr Charles Coombes. (Source: Medscape Oncology)
Source: Medscape Oncology - December 27, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

Do Hormonal Contraceptives Increase Breast Cancer Risk?
Dr Andrew Kaunitz disputes the recent findings from a Danish breast cancer risk study that primarily studied women in a lower-risk group. (Source: Medscape ObGyn Podcast)
Source: Medscape ObGyn Podcast - December 22, 2017 Category: OBGYN Authors: Medscape Source Type: podcasts

Hormonal Contraception and Risk for Breast Cancer: Many Caveats
This large-scale study is an important contribution to the literature, notes Dr JoAnn Manson, but should it change practice? (Source: Medscape Medscape Podcast)
Source: Medscape Medscape Podcast - December 13, 2017 Category: General Medicine Authors: Medscape Source Type: podcasts

Deep Learning Algorithms for Detection of Lymph Node Metastases From Breast Cancer
Interview with Jeffrey Alan. Golden, MD, author of Deep Learning Algorithms for Detection of Lymph Node Metastases From Breast Cancer: Helping Artificial Intelligence Be Seen (Source: JAMA Author Interviews)
Source: JAMA Author Interviews - December 12, 2017 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

Levothyroxine and miscarriage, AI detection of breast cancer mets and DM retinopathy, hormone therapy for chronic disease prevention, and more
Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the December 12, 2017 issue (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - December 12, 2017 Category: General Medicine Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts

Genetic Mutations Responsible For Breast Cancer
Dr Pierfranco Conte, Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Is Genomic Profiling Useful For Breast Cancer Patients?
Dr Pierfranco Conte, Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Immunotherapy For Breast Cancer Patients: Where Do We Stand?
Dr Pierfranco Conte, Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Treatment Options For Breast Cancer Patients With Metastatic Disease
Dr Pierfranco Conte, Professor of Oncology at the University of Padova and Director of the Division of Medical Oncology 2 at the Istituto Oncologico Veneto Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Twitter Has Given Me Power To Learn And Connect
Joanne Taylor, secondary breast cancer patient and Advocate, speaks from ESMO 2017 Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

My Work To Get Metastatic Cancer Data Collected
Joanne Taylor, secondary breast cancer patient and Advocate, speaks from ESMO 2017 Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

How I Advocate For Breast Cancer Patients
Joanne Taylor, secondary breast cancer patient and Advocate, speaks from ESMO 2017 Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Being At A Cancer Conference As An Advocate
Joanne Taylor, secondary breast cancer patient and Advocate, speaks from ESMO 2017 Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Genomic Profiling For Breast Cancer Patients
Dr Fatima Cardoso, Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal, speaks from ESMO 2017. Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

The Advanced Breast Cancer Global Alliance
Dr Fatima Cardoso, Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal, speaks from ESMO 2017. Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

ESMO 17: Advances For Metastatic Breast Cancer Patients
Dr Fatima Cardoso, Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal, speaks from ESMO 2017. Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

What Is The Role Of Immunotherapy In The Future Of Breast Cancer?
Dr Fatima Cardoso, Director of the Breast Unit of the Champalimaud Clinical Center in Lisbon, Portugal, speaks from ESMO 2017. Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Which Are The Main Breast Cancer Subtypes?
Professor Giuseppe Curigliano, Co-Chair of the Division of Medical Oncology at European Institute of Oncology (EIO), Clinician and Researcher specializing in Breast Cancer, speaks from ESMO 2017. Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Parp Inhibitors in BRCA Mutated Breast Cancer
Professor Giuseppe Curigliano, Co-Chair of the Division of Medical Oncology at European Institute of Oncology (EIO), Clinician and Researcher specializing in Breast Cancer, speaks from ESMO 2017. Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

How Genomic Profiling Is Benefiting Patients
Professor Giuseppe Curigliano, Co-Chair of the Division of Medical Oncology at European Institute of Oncology (EIO), Clinician and Researcher specializing in Breast Cancer, speaks from ESMO 2017. Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

: Is Immunotherapy An Option For Breast Cancer Patients?
Professor Giuseppe Curigliano, Co-Chair of the Division of Medical Oncology at European Institute of Oncology (EIO), Clinician and Researcher specializing in Breast Cancer, speaks from ESMO 2017. Author: patientpower Added: 10/19/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 19, 2017 Category: Cancer & Oncology Source Type: podcasts

Interactive Case: Choosing and Using CDK4/6 Inhibitors in Breast Cancer - First-line Therapy
The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-n... Author: imedex Added: 10/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 2, 2017 Category: Cancer & Oncology Source Type: podcasts

Interactive Case: Choosing and Using CDK4/6 Inhibitors for Breast Cancer - Second-line Therapy
The approvals of palbociclib and ribociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, provided advanced or metastatic hormone-positive, human epidermal growth factor receptor 2-n... Author: imedex Added: 10/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - October 2, 2017 Category: Cancer & Oncology Source Type: podcasts

PodMed – Week of September 18, 2017
This week’s topics include hospital factors relative to readmission, hormone therapy, lymph node dissection in breast cancer, and the cost of bringing a new drug to market. Program notes: 0:32 Cost of R and D versus profit in new drugs 1:32 Took 7.3 years 2:35 Reaping in sales far outstrips R and D 3:32 R […] (Source: Johns Hopkins Medicine Weekly Health News)
Source: Johns Hopkins Medicine Weekly Health News - September 15, 2017 Category: Consumer Health News Authors: Elizabeth Tracey Johns Hopkins Medicine Tags: All Podcasts Breast Health Cancer Patient Care PodMed Source Type: podcasts

Neratinib and Capecitabine for Patients with HER2+ Breast Cancer Brain Metastases (BCBM)
Daniela Bota, MD of UC Irvine Health discusses the use of neratinib and capecitabine in patients with breast cancer brain metastases at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beac... Author: moasc Added: 08/03/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2017 Category: Cancer & Oncology Source Type: podcasts

PALOMA-1: Palbociclib in Combination with Letrozole versus Letrozole Alone in Breast Cancer
Rita Mehta, MD of UC Irvine Health gives an overview of the PALOMA-1 trial and the use of palbociclib and letrozole in the treatment of ER+ and HER2-advanced breast cancer. This was recorded at the 20... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

OlympiAD: Olaparib versus Chemotherapy in HER2-Negative Metastatic Breast Cancer and a Germline BRCA Mutation
Rita Mehta, MD of UC Irvine Health gives an overview of the OlympiAD study, which focuses on the use of olaparib in HER2 negative metastatic breast cancer. This was recorded at the 2017 MOASC Spotligh... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

MONARCH 2: Abemaciclib with Fulvestrant in HR+/HER2-Positive Early Breast Cancer
Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib with fulvestrant in patients with HR+/HER2- Advanced Breast Cancer who have progressed on endocrine therapy.... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

MONARCH 2: Abemaciclib with Fulvestrant in HR+/HER2 Negative Advanced Breast Cancer
Rita Mehta, MD of UC Irvine Health discusses the MONARCH 2 trial and the use of abemaciclib and fulvestrant in advanced HR+/HER2 negative breast cancer progressing patients following prior endocrine t... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

APHINITY: Pertuzumab as Adjuvant Therapy in HER2-Positive Early Breast Cancer
Rita Mehta, MD of UC Irvine Health gives an overview of the APHINITY trial and the use of pertuzumab as adjuvant therapy for patients with HER2+ early breast cancer. This was recorded at the 2017 MOAS... Author: moasc Added: 08/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - August 2, 2017 Category: Cancer & Oncology Source Type: podcasts

Breast Cancer Due to Non –BRCA1 and Non–BRCA2 Mutations in Ashkenazi Jewish Women
Interview with Mary-Claire King, author of Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - July 20, 2017 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

JAMA Oncology : Breast Cancer Due to Non –BRCA1 and Non–BRCA2 Mutations in Ashkenazi Jewish Women
Interview with Mary-Claire King, author of Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - July 20, 2017 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

'GPS' for Breast Cancer Targets Therapy & amp; Improves Aesthetics after Breast Cancer Surgery
Surgeon Anne Peled, MD and patient Sue Yeres -- herself a breast cancer activist -- tell the story of Sue's healing after breast cancer, helped by the BioZorb implant. For more info, see http://ww...... Author: FocalTherapeutics Added: 07/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2017 Category: Cancer & Oncology Source Type: podcasts

BioZorb's Role in Breast Conserving Surgery
Dr. David Edmonson describes how the BioZorb implant helps improve cosmetic results for breast cancer patients -- while also aiding with the targeting of radiation treatment after surgery. Dr. Edmonso... Author: FocalTherapeutics Added: 07/17/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 17, 2017 Category: Cancer & Oncology Source Type: podcasts

Potential ASCO Practice-Changers in HER2+ Breast Cancer
Oncologists will debate the APHINITY trial data for years to come, says Dr Kevin Kalinsky. (Source: Medscape Oncology)
Source: Medscape Oncology - July 7, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts

ASCO 2017: Breast Cancer News
Will precision medicine become a part of standard treatment for breast cancer patients? Dr. Steven J. Isakoff of Massachusetts General Hospital Cancer Center, explains the evolution of treatment strat... Author: patientpower Added: 06/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2017 Category: Cancer & Oncology Source Type: podcasts

Annual Meeting 2017: Breast Cancer News
Will precision medicine become a part of standard treatment for breast cancer patients? Dr. Steven J. Isakoff of Massachusetts General Hospital Cancer Center, explains the evolution of treatment strat... Author: patientpower Added: 06/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2017 Category: Cancer & Oncology Source Type: podcasts

New CDK4/6i Data Move Metastatic Breast Cancer Field Forward
At ASCO 2017, the MONARCH-3, PALOMA-1, AND TREnd trials shed light on the efficacy of new CDK4/6 inhibitors for metastatic breast cancer. (Source: Medscape Oncology)
Source: Medscape Oncology - June 27, 2017 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts